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Antoine Adenis1,13*, Christelle de la Fouchardiere2, Bernard Paule3, Pascal Burtin4, David Tougeron5,
Jennifer Wallet6, Louis-Marie Dourthe7, Pierre-Luc Etienne8, Laurent Mineur9, Stéphanie Clisant10,
Jean-Marc Phelip11, Andrew Kramar6 and Thierry Andre12Erratum
After publication of the original article [1], an error
was noticed within the title: acronym “REBECCA”
was erroneously written as “REBACCA”. The original
article has now been updated with the correct title
which can also be found above. The publisher would like
to apologise for this error and for any inconvenience this
may have caused.
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